Wszystkie zdjęcia(1)



Acetohydroxamic acid

United States Pharmacopeia (USP) Reference Standard

Wzór liniowy:
Numer CAS:
Masa cząsteczkowa:
Numer MDL:
Identyfikator substancji w PubChem:

klasa czystości

pharmaceutical primary standard




88-90 °C (lit.)


pharmaceutical (small molecule)



SMILES string




InChI key


Szukasz podobnych produktów? Visit Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Komentarz do analizy

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Inne uwagi

USP issued SDS can be found here.
Sales restrictions may apply.


Health hazard

Hasło ostrzegawcze


Zwroty wskazujące rodzaj zagrożenia

Zwroty wskazujące środki ostrożności

Klasyfikacja zagrożeń

Repr. 1B

Kod klasy składowania

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects



Temperatura zapłonu °F

Not applicable

Temperatura zapłonu °C

Not applicable

Certyfikat analizy

Świadectwo pochodzenia

Więcej dokumentów

K D Lake et al.
Drug intelligence & clinical pharmacy, 19(7-8), 530-539 (1985-07-01)
Kidney stones have an overall incidence of two to three percent in western countries. In many patients, the disease process is difficult to control and recurrence rates are high: 20 to 50 percent over the subsequent ten years. The pathogenesis
Raymond L Benza et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 34(3), 329-337 (2014-07-08)
Pulmonary hypertension (PH) associated with left heart disease (World Health Organization [WHO] Group II) has previously been linked with significant morbidity and mortality. However, there are currently no approved therapies or hemodynamic monitoring systems to improve outcomes in WHO Group
Baris Gencer et al.
Atherosclerosis, 239(1), 118-124 (2015-01-15)
2013 AHA/ACC guidelines on the treatment of cholesterol advised to tailor high-intensity statin after ACS, while previous ATP-III recommended titration of statin to reach low-density lipoprotein cholesterol (LDL-C) targets. We simulated the impact of this change of paradigm on the
Saro H Armenian et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(6), 1109-1114 (2014-04-11)
Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully
Anne Tournadre et al.
International journal of cardiology, 183, 149-154 (2015-02-11)
Patients with rheumatoid arthritis (RA) have greater rates of cardiovascular mortality and RA is an independent cardiovascular risk factor. For the management of cholesterol, the American College of Cardiology/American Heart Association (ACC/AHA) developed new guidelines for the general population. None

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej